Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00478725 · ClinicalTrials.gov registry record · Phase 1
Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00478725 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 10 participants.
The verdict
NCT00478725, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
To study the absorption, distribution, metabolism and excretion of GW786034, and the absorption of a single IV dose of GW786034
Interventions
- DRUG GW786034, oral
- DRUG GW786034, IV
- DRUG GW786034, radiolabeled oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-07-18 |
| Est. Completion | 2008-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00478725
The ClinicalTrials.gov registry entry for NCT00478725 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which GW786034, oral is the first listed.
NCT00478725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00478725 about?
NCT00478725 is a clinical study titled "Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034". To study the absorption, distribution, metabolism and excretion of GW786034, and the absorption of a single IV dose of GW786034
What is the current status of trial NCT00478725?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2007-07-18. Estimated completion is 2008-07-01.
What interventions are being tested in trial NCT00478725?
The interventions under investigation include: GW786034, oral (DRUG), GW786034, IV (DRUG), GW786034, radiolabeled oral (DRUG).
Who is sponsoring clinical trial NCT00478725?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.